The Pharmaceutical Industry’s 10 Biggest R&D Budgets
Innovation is everything when it comes to the pharmaceutical sector.
Posts Tagged ‘Novartis A G (NVS)’
Everything You Need to Know About the Upcoming Flu Season
To me, flu season is a lot like Christmas; there's a defined time period when we expect it to occur, yet it seems to appear earlier and earlier every year.
Regeneron Pharmaceuticals Inc (REGN): Should You Follow in Sanofi SA (ADR) (SNY)’s Footsteps and Invest in This Booming Biotech?
More than anything, biotech companies need investors who are true believers in their products.
SPDR S&P Homebuilders (ETF) (XHB), Abercrombie & Fitch Co. (ANF), Novartis AG (ADR) (NVS): Shorts Are Piling Into These Stocks. Should You Be Worried?
The best thing about the stock market is that you can make money in either direction. Historically, stock indexes have tended to trend up over the long term.
GlaxoSmithKline plc (ADR) (GSK), Theravance Inc (THRX), Teva Pharmaceutical Industries Ltd (ADR) (TEVA): Could a Pair of Respiratory Disease Treatments Save This Big Pharma?
GlaxoSmithKline plc (ADR) (NYSE:GSK) and its partner Theravance Inc (NASDAQ:THRX) recently scored a second victory in their quest to treat chronic obstructive pulmonary disease...
Theravance Inc (THRX), GlaxoSmithKline plc (ADR) (GSK): Time to Bet on This Biotech Spinoff?
There hasn't been a dull moment for investors of Theravance Inc (NASDAQ:THRX) since the company submitted an NDA for COPD/asthma drug BREO before the Food and Drug Administration...
Ariad Pharmaceuticals, Inc. (ARIA), Pfizer Inc. (PFE), Novartis AG (ADR) (NVS): Does This Orphan Leukemia Treatment Have Blockbuster Potential?
When most biotech investors think of cancer treatments, they tend to think of large established players like Roche and Amgen.
Novartis AG (ADR) (NVS), Medtronic, Inc. (MDT): Will Smart Pills Revolutionize Health Care?
The ongoing convergence of the tech and health care industries has yielded some remarkable advances in telehealth, electronic health records, or EHRs, and mobile apps.
Pfizer Inc. (PFE), Novartis AG (ADR) (NVS): Will a Band-Aid Be Enough for Johnson & Johnson (JNJ)’s Latest Recall?
Johnson & Johnson (NYSE:JNJ) recently announced a recall of around 200,000 bottles of Motrin Infants' Drops Original Berry Flavor.
GlaxoSmithKline plc (ADR) (GSK), Pfizer Inc. (PFE): Theravance Inc (THRX) Gets Big Win for New COPD Drug
Trading of biopharmaceutical company Theravance Inc (NASDAQ:THRX) was halted on Tuesday. A major decision hung in the balance as the U.S.
Johnson & Johnson (JNJ), Novartis AG (ADR) (NVS): The Cooper Companies, Inc. (COO) Leveraging Share Gains for Eye-Opening Growth
The Cooper Companies, Inc. (NYSE:COO), or more formally "The Cooper Companies" is a sort of odd duck in the med-tech world.
Incyte Corporation (INCY), Pfizer Inc. (PFE): This Biotech Has So Many Reasons to Be Liked
Earlier this month, I wrote an article explaining that I liked Incyte Corporation (NASDAQ:INCY) on the basis of the blockbuster potential of its only approved drug, Jakafi...
Johnson & Johnson (JNJ), Forest Laboratories, Inc. (FRX), Pfizer Inc. (PFE): Pharmas Spending the Most to Catch Your Doctor’s Eye
Pharmaceutical firms spend a lot of money to influence physicians to prescribe their products.
Johnson & Johnson (JNJ), Pfizer Inc. (PFE), Novartis AG (ADR) (NVS): The Biggest Winners of the FDA’s Breakthrough Designation
Designed as a way to bring potentially life-changing drugs to pharmacy shelves faster than ever, the Food and Drug Administration Safety and Innovation Act, which passed last ...
Biogen Idec Inc. (BIIB), Incyte Corporation (INCY): Should Novartis AG (ADR) (NVS) Shareholders Be Worried About This?
As an investor in the health care sector, it can sometimes feel like everything -- and everyone -- is out to get you.
Eli Lilly & Co. (LLY), Novartis AG (ADR) (NVS), Shire PLC (ADR) (SHPG): A Closer Look at the Controversial Market Growth of ADHD Treatments
The existence of ADHD, or attention deficit hyperactivity disorder, has been a hot-button topic since the 1970s.
Incyte Corporation (INCY), Pacific Biosciences of California (PACB), Astex Pharmaceuticals, Inc. (ASTX): 3 Humongous Health-Care Stocks This Week
Incyte Corporation (NASDAQ:INCY) takes the top spot on our humongous health-care stocks list.
Amgen, Inc. (AMGN) and Onyx Pharmaceuticals, Inc. (ONXX): Half a Billion Dollars’ Worth of Drama
A finale has at last arrived for the biotech drama of summer 2013. Amgen, Inc. (NASDAQ:AMGN) announced yesterday that it will buy Onyx Pharmaceuticals, Inc.
Curis, Inc. (CRIS), Bristol Myers Squibb Co. (BMY), Novartis AG (ADR) (NVS): Can Stopping This Hedgehog Create New Cancer Treatments?
Curis, Inc. (NASDAQ:CRIS) and Roche Holding Ltd.
GTx, Inc. (GTXI), Novartis AG (ADR) (NVS): This Week in Biotech
With the SPDR S&P Biotech Index up 37% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector.
Community Health Systems (CYH), Novartis AG (ADR) (NVS): 7 Things You Need to Know About Obamacare Before 2014
Well, OK, many parts of the Patient Protection and Affordable Care Act, commonly referred to as Obamacare, have already been implemented.
Incyte Corporation (INCY), Gilead Sciences, Inc. (GILD): Pop-Worthy Data, Incyte, but Let’s See More
For a subgroup of the patients, the hazard ratio for overall survival in late-stage pancreatic cancer patients taking Incyte Corporation (NASDAQ:INCY)'s Jakafi and Roche's Xeloda...
Pfizer Inc. (PFE), Novartis AG (ADR) (NVS): Does Incyte Corporation (INCY) Deserve Its New Valuation?
One of the hottest stocks on the market Wednesday was Incyte Corporation (NASDAQ:INCY), a pharmaceutical company specializing in the development of JAK inhibitors.
Novartis AG (ADR) (NVS): Why Incyte Corporation (INCY) Shares Skyrocketed
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis...
Novartis AG (ADR) (NVS), Amgen, Inc. (AMGN): Incyte Corporation (INCY) Jumps on Jakafi Results
Incyte Corporation (NASDAQ:INCY) today announced positive results from a phase 2 study of its drug Jakafi in treating refractory metastatic pancreatic cancer.
Biogen Idec Inc. (BIIB), Teva Pharmaceutical Industries Ltd (ADR) (TEVA), Novartis AG (ADR) (NVS): Companies Leading the Fight Against Multiple Sclerosis
It's a disease that doesn't often find itself in the spotlight, but multiple sclerosis is quickly becoming an ailment that drugmakers are focusing their efforts on to make a quality...
Merck & Co., Inc. (MRK), Novartis AG (ADR) (NVS): One Hidden Pharmaceutical Technology for Your Portfolio
Pharmaceutical companies are always looking for competitive advantages.
GlaxoSmithKline plc (ADR) (GSK), Novartis AG (ADR) (NVS): This Company’s Debt Might Be a Concern
GlaxoSmithKline plc (ADR) (NYSE:GSK) has been accused of making illegal payments to Chinese doctors and government officials by siphoning them through travel agencies.
Roche Holding Ltd. (ADR) (RHHBY), Novartis AG (ADR) (NVS): Should You Keep an Eye on These Eye Treatment Biotechs?
Investors might want to keep their eyes on the eye care industry, as the battle for eye treatments heats up across the biotech sector.
Theravance Inc (THRX), Novartis AG (ADR) (NVS): Respiratory Drug Maker About to Take Off
Chronic obstructive pulmonary disease (COPD) is America’s third leading cause of death.
Eli Lilly & Co. (LLY), Novartis AG (ADR) (NVS): Is This Company Getting Ahead of Itself?
The biotechnology industry is one of the riskiest places to put your money. However, when companies get everything right, the fortunes made there are usually massive.
Celgene Corporation (CELG), Novartis AG (ADR) (NVS): Momenta Pharmaceuticals, Inc. (MNTA) Earnings Remind Investors of Growing Pains
The investing waters can get pretty choppy from time to time with a developmental stage company. A look at the five-year chart of Momenta Pharmaceuticals, Inc.
3 Things You Need to Know From Astex Pharmaceuticals, Inc. (ASTX)’s Q2 Earnings
Astex Pharmaceuticals, Inc. (NASDAQ:ASTX) announced its second-quarter financial results on Thursday prior to the market open.
Amgen, Inc. (AMGN), Baxter International Inc. (BAX): Can the FDA Make Up Its Mind Already?
It isn't very often that an agency sometimes accused of over-regulating an industry can be ridiculed for not regulating enough, but that's exactly where the Food and Drug Administration...
Incyte Corporation (INCY) Earnings Cruise on Jakafi Growth
Budding biotech company Incyte Corporation (NASDAQ:INCY), which specializes in developing novel JAK inhibitors, released solid second-quarter earnings on Wednesday.
Biogen Idec Inc (BIIB), Pfizer Inc. (PFE): Out With the Old, In With the New in Treating MS
Hidden beneath all the numbers and metrics in Biogen Idec Inc (NASDAQ:BIIB)'s recent earnings report is a key confirmation of a shifting market in the treatment of multiple sclerosis...
Theravance Inc (THRX), GlaxoSmithKline plc (ADR) (GSK): Which of These COPD Treatments Will Come Out on Top?
To most people, cigarettes are often associated with lung cancer.
Alexion Pharmaceuticals, Inc. (ALXN): Extremely Expensive Drugs for Extremely Rare Diseases
The biotech industry is known for fast paced acquisitions and rapid market consolidation.
Momenta Pharmaceuticals, Inc. (MNTA) Latest to Take Advantage of Teva Pharmaceutical Industries Ltd (ADR) (TEVA)’s Patent Woes
The United States Court of Appeals is making this one miserable summer for Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA).
Pfizer Inc. (PFE): As Healthcare Demand Rises, So Will This Company’s Profits
The aging population as well as the higher number of people who will receive benefits under new healthcare laws should combine to produce rising profits for a variety of companies...
Onyx Pharmaceuticals, Inc. (ONXX), Amgen, Inc. (AMGN): Will This Biotech Bidding War Lead You to Larger Gains?
Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) added 3% to its one-month 60% gains on Monday because of continued speculation of a buyout.
Alkermes Plc (ALKS), Quest Diagnostics Inc (DGX): This Week in Biotech
With the SPDR S&P Biotech Index up 31% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector.
A Look at Novartis AG (ADR) (NVS)’ Second Quarter
The story of the second quarter for Novartis AG (ADR) (NYSE:NVS) offered mixed results for investors. The company's net sales were up 1%, and EPS was down 6% year over year.
Pfizer Inc. (PFE), Merck & Co., Inc. (MRK): Which Pharmaceutical Giant Is the Best Investment?
Amid sluggish sales growth, the Pharmaceutical Industry giants are struggling with declining revenues and profits.
Merck & Co., Inc. (MRK): This Pharmaceutical Company Is Poised for Wellness
Sustainability and a strong pipeline are the two tests that best evaluate a pharmaceutical company. Merck & Co., Inc. (NYSE:MRK) scores high on both counts.
GlaxoSmithKline plc (ADR) (GSK), Theravance Inc (THRX), Pfizer Inc. (PFE): 3 Potential Game Changers for COPD
Over 13 million Americans have it. More than 120,000 of them die every year.
Jazz Pharmaceuticals plc – Ordinary Shares (JAZZ), Novartis AG (ADR) (NVS): Don’t Let Your Attention Defect
Ineffective drugs being sold for billions in global sales.
The Boeing Company (BA), Lockheed Martin Corporation (LMT) – Pentagon Watch: Where Did Your Tax Dollars Go This Week?
The U.S. military has a reputation as a somewhat secretive organization. But in one respect at least, the Pentagon ranks among our most transparent government agencies.
